Evidence map›Paper›PMID 26238225›Full record

Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2015

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.

Daniel Weintraub, Lea T Drye, Anton P Porsteinsson, Paul B Rosenberg, Bruce G Pollock, Devangere P Devanand, Constantine Frangakis, Zahinoor Ismail, Christopher Marano, Curtis L Meinert and 9 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Diagnosis and Treatment of Alzheimer's Disease:: An Update.Delaware journal of public health · 2021
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 2 countries.

Daniel WeintraubPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: daniel.weintraub@uphs.upenn.edu.
Lea T DryeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Anton P PorsteinssonUniversity of Rochester School of Medicine and Dentistry, Rochester, NY.
Paul B RosenbergJohns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, MD.
Bruce G PollockCampbell Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Devangere P DevanandDivision of Geriatric Psychiatry, New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, New York, NY.
Constantine FrangakisJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Zahinoor IsmailDepartments of Psychiatry and Neurology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Christopher MaranoJohns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, MD.
Curtis L MeinertJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Jacobo E MintzerClinical Biotechnology Research Institute, Roper St. Francis Healthcare, Charleston, SC.
Cynthia A MunroJohns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, MD.
Gregory PeltonDivision of Geriatric Psychiatry, New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, New York, NY.
Peter V RabinsJohns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, MD.
Lon S SchneiderUniversity of Southern California Keck School of Medicine, Los Angeles, CA.
David M ShadeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Jerome YesavageStanford University School of Medicine and VA Palo Alto Health Care System, Stanford, CA.
Constantine G LyketsosJohns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, MD.
CitAD Research Group
Johns Hopkins University · USColumbia University · USJohns Hopkins Bayview Medical Center · USRoper St. Francis Healthcare · USStanford University · USUniversity of Calgary · CAUniversity of Pennsylvania · USUniversity of Rochester · USUniversity of Southern California · USUniversity of Toronto · CA

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KIM, PAUL E · 1985 to 2019
$41.0M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
Citalopram Treatment for Agitation in Alzheimer DementiaR01AG031348 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 2008 to 2012
$7.9M
Insulin Resistance in Late-Life DepressionK23MH095971 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MARANO, CHRISTOPHER · 2012 to 2016
$903k
NCATS NIH HHS UL1 TR001079NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS P50 AG05142NIA NIH HHS R01 AG031348NIA NIH HHS R01AG031348NIMH NIH HHS K23 MH095971
6 · The paper itself

Abstract

objectiveAgitation is a common and significant problem in Alzheimer disease (AD). In the recent Citalopram for Agitation in Alzheimer's Disease (CitAD) study, citalopram was efficacious for the treatment of AD agitation. Here we examined the time course and predictors of response to treatment.

methodsResponse in CitAD was defined as a modified Alzheimer Disease Cooperative Study Clinical Global Impression of Change (CGIC) score of 1 or 2 or a Neurobehavioral Rating Scale agitation subscale (NBRS-A) score reduction ≥ 50% from baseline. "Stable early response" was defined as meeting the aforementioned criteria at both weeks 3 and 9, "late response" was response at week 9 but not at week 3, and "unstable response" was response at week 3 but not at week 9.

resultsIn the primary analyses, citalopram was superior to placebo on both the CGIC and the NBRS-A response measures. Little between-group differences were found in response rates in the first 3 weeks of the study (21% versus 19% on the CGIC). Citalopram patients were more likely than placebo patients to be a late responder (18% versus 8% on CGIC, Fisher's exact p = 0.09; 31% versus 15% on NBRS-A, Fisher's exact p = 0.02). Approximately half of citalopram responders (45%-56%) at end of study achieved response later in the study compared with 30%-44% of placebo responders.

conclusionTreatment with citalopram for agitation in AD needs to be at least 9 weeks in duration to allow sufficient time for full response. Study duration is an important factor to consider in the design of clinical trials for agitation in AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseCitalopramDouble-Blind MethodFemaleHumansMalePsychiatric Status Rating ScalesPsychomotor AgitationSelective Serotonin Reuptake InhibitorsTime FactorsTreatment OutcomeCitalopramSelective Serotonin Reuptake InhibitorsAgitationAlzheimer diseasecitalopram

Identifiers

PMID26238225
PMCPMC4653092
OpenAlexW1044629086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.